Table 1.

Baseline characteristics and serum protectin levels of the patients with diabetes who underwent percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS).

Variables	Serum calprotectin level (μg/mL)		P-value
	<4.1 μg/mL (n=122)	≥4.1 μg/mL (n=151)
Demographic characteristics
Age, years	59.5±7.2	61.2±7.6	0.06
Male	74 (60.7%)	95 (62.9%)	0.70
BMI, kg/m2	25.6±2.8	25.9±3.2	0.42
Underlying diseases
Hypertension	79 (64.8%)	93 (61.6%)	0.29
Hyperlipidemia	66 (54.1%)	76 (50.3%)	0.54
Chronic kidney disease	55 (45.1%)	73 (48.3%)	0.59
Medication
OHA	31 (25.4%)	41 (27.2%)	0.75
Insulin	56 (45.9%)	80 (52.9%)	0.24
ACEIs/ARBs	88 (72.1%)	106 (70.2%)	0.73
Statins	112 (92.6%)	139 (92.1%)	0.94
Beta-blockers	91 (75.2%)	109 (72.2%)	0.66
Laboratory tests
LDL-C, mmol/l	2.28±0.52	2.26±0.54	0.76
HDL-C, mmol/l	1.32±0.22	0.94±0.21	<0.01
TC, mmol/l	4.33±1.07	4.36±1.02	0.81
TG, mmol/l	2.11±1.13	2.13±1.26	0.04
FPG, mmol/l	7.22±1.45	9.46±1.89	<0.01
HbA1c,%	7.12±1.24	7.22±1.63	0.58
Cr, μmol/l	78.12±12.11	76.82±16.82	0.47
eGFR, ml/min/1.73 m2	72.26±23.46	68.82±18.73	0.18
hs-CRP (ng/ml)	6.65±4.71	8.61±5.98	<0.01
PCI related data
Number of stents, per case	1.71±1.12	1.73±1.14	0.88
GRACE score	132.16±37.22	143.52±35.68	0.01
LVEF, %	54.23±11.05	53.32±10.11	0.48
LAD, mm	31.42±2.62	32.12±4.62	0.14

DM – diabetes mellitus; BMI – body mass index; OHA – oral hypoglycemic agent; ACEIs – angiotensin-converting enzyme inhibitors; ARBs – angiotensin receptor blockers; LDL-C – low-density lipoprotein cholesterol; HDL-C – high-density lipoprotein cholesterol; FPG – fasting plasma glucose; TC – total cholesterol; TG – triglycerides; Cr – creatinine. LVEF – left ventricular ejection fraction; LAD – left atrial diameter; GRACE – Global Registry of Acute Coronary Events.